Extendicare Past Earnings Performance
Past criteria checks 2/6
Extendicare has been growing earnings at an average annual rate of 0.3%, while the Healthcare industry saw earnings growing at 0.3% annually. Revenues have been growing at an average rate of 2.8% per year. Extendicare's return on equity is 38.7%, and it has net margins of 2.6%.
Key information
0.3%
Earnings growth rate
1.0%
EPS growth rate
| Healthcare Industry Growth | -6.7% |
| Revenue growth rate | 2.8% |
| Return on equity | 38.7% |
| Net Margin | 2.6% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
There May Be Underlying Issues With The Quality Of Extendicare's (TSE:EXE) Earnings
Mar 16
Extendicare (TSE:EXE) Has Announced A Dividend Of CA$0.04
Oct 19Extendicare (TSE:EXE) Will Pay A Dividend Of CA$0.04
Sep 21Extendicare (TSE:EXE) Has Announced A Dividend Of CA$0.04
Aug 24Extendicare's (TSE:EXE) Dividend Will Be CA$0.04
Jul 20Extendicare (TSE:EXE) Is Due To Pay A Dividend Of CA$0.04
Jun 20Extendicare (TSE:EXE) Has Affirmed Its Dividend Of CA$0.04
May 18Is Extendicare (TSE:EXE) Using Too Much Debt?
May 11Extendicare (TSE:EXE) Is Due To Pay A Dividend Of CA$0.04
Jan 20Extendicare (TSE:EXE) Will Pay A Dividend Of CA$0.04
Aug 17Extendicare (TSE:EXE) Has Affirmed Its Dividend Of CA$0.04
Apr 22Extendicare (TSE:EXE) Will Pay A Dividend Of CA$0.04
Mar 22Extendicare (TSE:EXE) Is Due To Pay A Dividend Of CA$0.04
Feb 18Revenue & Expenses BreakdownBeta
How Extendicare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,305 | 34 | 56 | 0 |
| 30 Sep 23 | 1,265 | 18 | 55 | 0 |
| 30 Jun 23 | 1,252 | 1 | 53 | 0 |
| 31 Mar 23 | 1,241 | 3 | 52 | 0 |
| 31 Dec 22 | 1,222 | -5 | 51 | 0 |
| 30 Sep 22 | 1,217 | -1 | 55 | 0 |
| 30 Jun 22 | 1,193 | 6 | 51 | 0 |
| 31 Mar 22 | 1,178 | 4 | 53 | 0 |
| 31 Dec 21 | 1,167 | 8 | 52 | 0 |
| 30 Sep 21 | 1,114 | 27 | 49 | 0 |
| 30 Jun 21 | 1,126 | 59 | 51 | 0 |
| 31 Mar 21 | 1,127 | 49 | 47 | 0 |
| 31 Dec 20 | 1,104 | 42 | 45 | 0 |
| 30 Sep 20 | 1,141 | 31 | 42 | 0 |
| 30 Jun 20 | 1,127 | 2 | 41 | 0 |
| 31 Mar 20 | 1,129 | 15 | 41 | 0 |
| 31 Dec 19 | 1,132 | 15 | 41 | 0 |
| 30 Sep 19 | 1,130 | 1 | 41 | 0 |
| 30 Jun 19 | 1,127 | 4 | 42 | 0 |
| 31 Mar 19 | 1,123 | 6 | 41 | 0 |
| 31 Dec 18 | 1,120 | 8 | 40 | 0 |
| 30 Sep 18 | 1,113 | 27 | 37 | 0 |
| 30 Jun 18 | 1,106 | 26 | 37 | 0 |
| 31 Mar 18 | 1,100 | 30 | 37 | 0 |
| 31 Dec 17 | 1,097 | 32 | 38 | 0 |
| 30 Sep 17 | 1,093 | 35 | 40 | 0 |
| 30 Jun 17 | 1,088 | 38 | 38 | 0 |
| 31 Mar 17 | 1,075 | 38 | 37 | 0 |
| 31 Dec 16 | 1,061 | 31 | 37 | 0 |
| 30 Sep 16 | 1,046 | 25 | 38 | 0 |
| 30 Jun 16 | 1,032 | 27 | 38 | 0 |
| 31 Mar 16 | 1,005 | 21 | 38 | 0 |
| 31 Dec 15 | 943 | 24 | 36 | 0 |
| 30 Sep 15 | 894 | 24 | 33 | 0 |
| 30 Jun 15 | 848 | 16 | 32 | 0 |
| 31 Mar 15 | 815 | 14 | 33 | 0 |
| 31 Dec 14 | 816 | 11 | 33 | 0 |
| 30 Sep 14 | -118 | 2 | 7 | 0 |
| 30 Jun 14 | 183 | 4 | 16 | 0 |
| 31 Mar 14 | 480 | 9 | 26 | 0 |
| 31 Dec 13 | 784 | 10 | 37 | 0 |
| 30 Sep 13 | 2,002 | 26 | 74 | 0 |
| 30 Jun 13 | 1,992 | 15 | 74 | 0 |
Quality Earnings: EXE has a high level of non-cash earnings.
Growing Profit Margin: EXE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EXE's earnings have grown by 0.3% per year over the past 5 years.
Accelerating Growth: EXE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EXE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (2.5%).
Return on Equity
High ROE: Whilst EXE's Return on Equity (38.65%) is high, this metric is skewed due to their high level of debt.